Biotechnology company Curis Inc (NASDAQ:CRIS) disclosed on Tuesday its net loss of USD32.6m (USD0.98 per share, basic and diluted basis) for year ended 31 December 2018.

This marks a rise in earnings when compared with a net loss of USD53.3m (USD1.79 per share, basic and diluted basis) in 2017.

Revenues of USD10.4m were generated for the year ended 31 December 2018, up over revenues of USD9.9m for the same period in 2017.

Research and development expenses of USD24.4m were recorded for the year ended 31 December 2018, a decline versus USD45.1m for the same period in 2017, primarily due to aggregate payments to Aurigene for an exclusivity option that was paid in 2017 as well as decreased costs related to ongoing clinical activities for CA-170.